JP4029041B2 - ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法 - Google Patents

ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法 Download PDF

Info

Publication number
JP4029041B2
JP4029041B2 JP2002556615A JP2002556615A JP4029041B2 JP 4029041 B2 JP4029041 B2 JP 4029041B2 JP 2002556615 A JP2002556615 A JP 2002556615A JP 2002556615 A JP2002556615 A JP 2002556615A JP 4029041 B2 JP4029041 B2 JP 4029041B2
Authority
JP
Japan
Prior art keywords
seq
sfrp
peptide
amino acid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002556615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501508A5 (enExample
JP2005501508A (ja
Inventor
ジェフリー エス． ルービン
アイカット ウレン
ニコル ジョイ ホーウッド
マシュー トッド ギレスピー
ブライアン ケイ． カイ
ベルナード ウェイスブラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2005501508A publication Critical patent/JP2005501508A/ja
Publication of JP2005501508A5 publication Critical patent/JP2005501508A5/ja
Application granted granted Critical
Publication of JP4029041B2 publication Critical patent/JP4029041B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0643—Osteoclasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
JP2002556615A 2001-01-10 2002-01-10 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法 Expired - Lifetime JP4029041B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26090801P 2001-01-10 2001-01-10
PCT/US2002/000869 WO2002055547A2 (en) 2001-01-10 2002-01-10 Sfrp and peptide motifs that interact with sfrp and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007120533A Division JP4248583B2 (ja) 2001-01-10 2007-05-01 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法

Publications (3)

Publication Number Publication Date
JP2005501508A JP2005501508A (ja) 2005-01-20
JP2005501508A5 JP2005501508A5 (enExample) 2005-09-02
JP4029041B2 true JP4029041B2 (ja) 2008-01-09

Family

ID=22991151

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002556615A Expired - Lifetime JP4029041B2 (ja) 2001-01-10 2002-01-10 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
JP2007120533A Expired - Lifetime JP4248583B2 (ja) 2001-01-10 2007-05-01 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
JP2008169716A Expired - Lifetime JP4248600B2 (ja) 2001-01-10 2008-06-30 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007120533A Expired - Lifetime JP4248583B2 (ja) 2001-01-10 2007-05-01 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
JP2008169716A Expired - Lifetime JP4248600B2 (ja) 2001-01-10 2008-06-30 ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法

Country Status (11)

Country Link
US (2) US7488710B2 (enExample)
EP (1) EP1387854B1 (enExample)
JP (3) JP4029041B2 (enExample)
AT (1) ATE550345T1 (enExample)
AU (1) AU2002241859B2 (enExample)
CA (1) CA2434672C (enExample)
CY (1) CY1112875T1 (enExample)
DK (1) DK1387854T3 (enExample)
ES (1) ES2385666T3 (enExample)
PT (1) PT1387854E (enExample)
WO (1) WO2002055547A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4832291B2 (ja) * 2004-03-31 2011-12-07 一男 新家 ラベル用物質とキメラ物質、これらの物質の作製方法、並びに該ラベル用物質を用いて生体物質を捕捉、構造解析又は／及び同定する方法
EP1831254B1 (en) * 2004-12-23 2012-06-06 Molmed SpA Conjugation product
WO2008061029A1 (en) * 2006-11-10 2008-05-22 Wyeth Aryl sulfonamide derivatives and methods of their use
AU2009226161A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry peptides across the blood brain barrier
PL2591683T3 (pl) * 2008-05-16 2017-07-31 Siebte Pmi Verwaltungs Gmbh Koncentraty białkowe z nasion oleistych i sposoby ich wytwarzania
JP2013006783A (ja) * 2011-06-22 2013-01-10 Nagasaki Univ 荷重感知遺伝子
PT3116521T (pt) * 2014-03-14 2024-10-15 Univ New York State Res Found Regulação neurogénica de crescimento ósseo e degradação óssea
CA2948071C (en) 2014-05-07 2022-08-30 Boehringer Ingelheim International Gmbh Container, nebulizer and use
WO2018229774A1 (en) * 2017-06-15 2018-12-20 Technion Research & Development Foundation Limited Compositions and methods for detection of genomic variations
EP3696192A1 (en) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238839A (en) * 1988-02-09 1993-08-24 Dana Farber Cancer Institute Nucleic Acids Encoding proteins which induce immunological effector cell activation and chemattraction, vectors, and recombinant cells
US5204328A (en) * 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
JPH07503944A (ja) * 1991-11-22 1995-04-27 イエダ　リサーチ　アンド　デベロツプメント　カンパニー　リミテツド Ａｒｇ−ｇｌｙ−ａｓｐ配列の非ペプチド代替物およびそれらからなる医薬組成物
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5726156A (en) 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5846932A (en) * 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
AU2664797A (en) 1996-04-12 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Wnt receptor compositions and methods
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ATE318915T1 (de) 1996-09-24 2006-03-15 Tanox Inc Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US5939271A (en) * 1997-02-19 1999-08-17 The Regents Of The University Of California Netrin receptor
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
EP0887408A1 (en) * 1997-05-23 1998-12-30 Smithkline Beecham Plc Wnt-3 oncogene: polypeptides and polynucleotides
US6479255B1 (en) * 1997-05-29 2002-11-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polynucleotides encoding human FRP and fragments thereof
WO1999009152A1 (en) 1997-08-12 1999-02-25 Human Genome Sciences, Inc. Human frezzled-like protein
WO1999026960A2 (en) 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes encoding frizzled-like proteins
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11196864A (ja) * 1998-01-08 1999-07-27 Deinabekku Kenkyusho:Kk 破骨細胞の分化を誘導する方法
US6110718A (en) * 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
IL148421A0 (en) 1999-09-13 2002-09-12 American Home Prod Pharmaceutical compositions and methods of using secreted frizzled related protein
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
JP2002181893A (ja) * 2000-12-11 2002-06-26 Mitsubishi Electric Corp 半導体装置の検査方法および検査装置

Also Published As

Publication number Publication date
JP2009005704A (ja) 2009-01-15
EP1387854A2 (en) 2004-02-11
JP2007300920A (ja) 2007-11-22
US20040077828A1 (en) 2004-04-22
JP4248600B2 (ja) 2009-04-02
PT1387854E (pt) 2012-06-26
ATE550345T1 (de) 2012-04-15
CA2434672C (en) 2014-03-25
CA2434672A1 (en) 2002-07-18
WO2002055547A3 (en) 2003-11-20
EP1387854B1 (en) 2012-03-21
JP4248583B2 (ja) 2009-04-02
DK1387854T3 (da) 2012-07-09
WO2002055547A9 (en) 2002-10-31
US7488710B2 (en) 2009-02-10
US20080145884A1 (en) 2008-06-19
ES2385666T3 (es) 2012-07-30
US8334260B2 (en) 2012-12-18
WO2002055547A2 (en) 2002-07-18
AU2002241859B2 (en) 2007-07-19
CY1112875T1 (el) 2016-04-13
JP2005501508A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
JP4248600B2 (ja) ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
US20240101625A1 (en) Epha2 t-cell epitope agonists and uses therefore
JP2022044589A (ja) ＡｃｔＲＩＩＢから誘導されたバリアントおよびその使用
CA2412612C (en) Eg-vegf nucleic acids and polypeptides and methods of use
CA2505250A1 (en) Acetylated hmgb1 protein
EP1771557B1 (en) GDF3 Propeptides and Related Methods
US20150209407A1 (en) Methods for the treatment and prevention of osteoporosis and bone-related diseases
JP4530129B2 (ja) スーパー抗原
EP3577462A1 (en) Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
AU2002241859A1 (en) sFRP and peptide motifs that interact with sFRP and methods of their use
JP2010285448A (ja) 骨発生の調節方法
WO2008127066A1 (en) Peptide inhibitors of receptor activator of nf-kb, and pharmaceutical composition including the same
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
WO1996000240A1 (en) Novel protein and process for producing the same
US7223853B2 (en) Secreted frizzled related protein fragments
US20080241129A1 (en) Adipocyte secreted protein ccdc80 is a potent stimulator of bone formation
WO1998037195A9 (en) Morphogenic proteins
EP0968285A1 (en) Morphogenic proteins
HK1059452B (en) Eg-vegf nucleic acids and polypeptides and methods of use

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071015

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4029041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111019

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121019

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121019

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131019

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term